Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

11294	Companies
250988	Keywords
179908	Articles
136855	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 2 years 3 months ago

Biophytis déploie sa stratégie de partenariats et signe deux contrats avec des agents locaux en Asie
Biophytis annonce le déploiement de sa stratégie de partenariats en Asie en signant deux contrats avec des agents locaux pour BIO101 afin d'accélérer son développement sur les marchés clés comme le Japon et la Chine

Biophytis Partenariats Asie Contrats BIO101
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 2 years 3 months ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis implements partnership strategy in Asia with new contracts to advance drug candidate BIO101 in Japan, South Korea, China, and Southeast Asia

Biophytis Asia Contracts Partnership Strategy Drug Candidate BIO101
BRIEF

published on 07/11/2024 at 08:18, 2 years 3 months ago

Biophytis Obtains IND Approval from FDA for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Clinical Trial BIO101 Obesity Study
BRIEF

published on 07/11/2024 at 08:18, 2 years 3 months ago

Biophytis obtient l'approbation IND de la FDA pour une étude de phase 2 sur l'obésité

Biophytis Approbation De La FDA Essai Clinique De Phase 2 BIO101 Étude Sur L'obésité
PRESS RELEASE

published on 07/11/2024 at 08:13, 2 years 3 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis receives FDA IND approval for phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by renowned expert Marc-André Cornier

FDA Biophytis Obesity IND Approval OBA Study
PRESS RELEASE

published on 07/11/2024 at 08:13, 2 years 3 months ago

Biophytis obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité
Biophytis obtient l'autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l'obésité. L'étude vise à mesurer l'amélioration de la force musculaire et la composition corporelle

FDA Biophytis Obésité Autorisation IND Étude OBA
BRIEF

published on 07/11/2024 at 07:06, 2 years 3 months ago

Biophytis obtient l’autorisation IND de la FDA pour une étude de phase 2 dans l’obésité

FDA Biophytis Étude Clinique BIO101 Obésité
BRIEF

published on 07/11/2024 at 07:06, 2 years 3 months ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity
REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 2 years 3 months ago

Biophytis obtient l’autorisation IND de la FDA pour démarrer son étude OBA de phase 2 dans l’obésité
Biophytis obtient l'autorisation IND de la FDA pour lancer l'étude OBA de phase 2 dans l'obésité avec BIO101 (20-hydroxyecdysone), visant à améliorer la force musculaire. Le professeur Marc-André Cornier dirigera l'étude multicentrique aux Etats-Unis

Biophytis BIO101 Obésité Autorisation IND Étude OBA
REGULATED PRESS RELEASE

published on 07/11/2024 at 07:01, 2 years 3 months ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis obtains FDA approval to start phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by Prof. Marc-André Cornier to start mid-2024 in the USA

Biophytis FDA Approval Obesity Treatment BIO101 Phase 2 OBA Study

Accesswire

Published on 11/06/2026 at 22:15, 2 days 9 hours ago

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 18 hours ago

Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 19 hours ago

Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 19 hours ago

Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 10:00, 2 days 21 hours ago

Mongolia Tax Audit

View all ACCESSWIRE

EQS Group

Published on 11/09/2026 at 07:30, 24 minutes ago

Hannover Re increases Group profit and confirms full-year guidance
Published on 11/09/2026 at 07:30, 25 minutes ago

SUSS Expands Photomask Portfolio with Next-Generation ASC9500 Mid-End Cleaner
Published on 11/09/2026 at 07:30, 25 minutes ago

GEA delivers strong third quarter: order intake rises substantially, revenue and profitability further improved
Published on 11/09/2026 at 07:30, 25 minutes ago

Nordex Group to enter Albania with 84 MW order from Verbund
Published on 11/09/2026 at 07:30, 25 minutes ago

q.beyond posts high volume of one-off charges in Q3 2026 – restructuring set to pay off from 2027 onwards

Les Echos

Published on 11/09/2026 at 07:00, 55 minutes ago

bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 55 minutes ago

BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 55 minutes ago

Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
Published on 11/09/2026 at 07:00, 55 minutes ago

bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour les dernières versions des tests BIOFIRE® FILMARRAY® Gastrointestinal Panels afin d’optimiser la détection des pathogènes gastrointestinaux, dont le norovirus
Published on 11/06/2026 at 19:06, 2 days 12 hours ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026

View all LES ECHOS COMFI WIRE